Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

347 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Bonneterre J, Chevallier B, Metz R, Fargeot P, Pujade-Lauraine E, Spielmann M, Tubiana-Hulin M, Paes D, Bons J. Bonneterre J, et al. Among authors: metz r. J Clin Oncol. 1990 Jun;8(6):1063-9. doi: 10.1200/JCO.1990.8.6.1063. J Clin Oncol. 1990. PMID: 2140854 Clinical Trial.
Phase II clinical evaluation of doxifluridine.
Hurteloup P, Armand JP, Cappelaere P, Metz R, Kerbrat P, Keiling R, Fumoleau P, Fargeot P, Schraub S, Bastit P, et al. Hurteloup P, et al. Among authors: metz r. Cancer Treat Rep. 1986 Jun;70(6):731-7. Cancer Treat Rep. 1986. PMID: 2942245
Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Misset JL, di Palma M, Delgado M, Plagne R, Chollet P, Fumoleau P, Le Mevel B, Belpomme D, Guerrin J, Fargeot P, Metz R, Ithzaki M, Hill C, Mathé G. Misset JL, et al. Among authors: metz r. J Clin Oncol. 1996 Apr;14(4):1136-45. doi: 10.1200/JCO.1996.14.4.1136. J Clin Oncol. 1996. PMID: 8648368 Clinical Trial.
Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC).
Chauvergne J, Fumoleau P, Cappelaere P, Metz R, Armand JP, Chevallier B, Kerbrat P, de Forni M, Lhommé C, Roche H, et al. Chauvergne J, et al. Among authors: metz r. Eur J Cancer. 1993;29A(3):350-4. doi: 10.1016/0959-8049(93)90384-r. Eur J Cancer. 1993. PMID: 8398333 Clinical Trial.
Follow-up results from a randomized trial for T3 and T4 breast cancer patients: previous BCG immunotherapy improves response to chemotherapy in the relapse patient.
Serrou B, Sancho-Garnier H, Cappelaere P, Plagne R, Metz R, Schneider M, Chollet P, Namer N, Pujol H, Gary-Bobo J, Meyer G, Mathé G. Serrou B, et al. Among authors: metz r. Recent Results Cancer Res. 1982;80:157-61. doi: 10.1007/978-3-642-81685-7_26. Recent Results Cancer Res. 1982. PMID: 7036278 Clinical Trial.
347 results